Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
95 GF Score
Price ¥42.91
GF Value ¥46.50
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Chengdu Easton Biopharmaceuticals Co Quality Rank Related Terms

SHSE:688513
95GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be undervalued. The current stock price of ¥42.91 is trading 7.7% below its estimated GF Value™ of ¥46.50. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.

Key valuation signals for SHSE:688513:

  • Quality Rank:
  • GF Value™: ¥46.50 vs. price of ¥42.91 (7.7% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score

Get the complete analysis for SHSE:688513

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥42.91
Price
¥46.50
GF Value